Pfizer slashed in half the volume of Covid-19 vaccines the company will deliver to some EU countries this week, government officials said, as frustration over the U.S. drugmaker’s unexpected cut in supplies grows.

AstraZeneca Plc’s cancer drug Imfinzi was approved in Europe and Britain for a spaced-out regimen in a common type of lung cancer to help reduce the frequency of hospital visits while continuing treatment.

The European Commission approved Swiss drugmaker Roche’s Xofluza to treat influenza in patients aged 12 years and older, the first new influenza antiviral for patients in almost 20 years.

The United States Department of Defense (DOD) awarded Moderna a contract valued at $1,966,598,000 for an additional 100 million doses of the company’s Covid-19 vaccine.

Europe launched a cross-border vaccination program of unprecedented scale on Dec. 27 as part of efforts to end the Covid-19 pandemic that has crippled economies and claimed more than 1.7 million lives around the world.

The European Commission approved Aimmune Therapeutics Inc.’s Palforzia for the treatment of peanut allergy.

Sanofi and Regeneron’s Dupixent product won approval from the European Commission to treat children aged 6-11 years suffering from severe atopic dermatitis, often known as eczema.

The European Commission wants to make it easier for patients to access cheaper generic medicines, a draft EU document seen by Reuters shows, in a move that could cut the revenues of big pharmaceutical firms.

Moderna will charge governments between $25 and $37 per dose of the company’s Covid-19 vaccine candidate, depending on the amount ordered, Chief Executive Stephane Bancel told German weekly Welt am Sonntag (WamS).

Gilead’s remdesivir should not be used for patients hospitalized with Covid-19, regardless of how ill they are, as there is no evidence the drug improves survival or reduces the need for ventilation, a World Health Organization panel said.